These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 34224026

  • 1. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
    Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S, Asioli GM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S.
    Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
    [Abstract] [Full Text] [Related]

  • 2. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D.
    J Headache Pain; 2020 Jul 03; 21(1):84. PubMed ID: 32620151
    [Abstract] [Full Text] [Related]

  • 3. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M, Tullo V, Didier HA, Bussone G.
    Neurol Sci; 2022 Sep 03; 43(9):5759-5761. PubMed ID: 35836032
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M, Leroux E, Pagé G.
    Clin Drug Investig; 2021 Aug 03; 41(8):733-739. PubMed ID: 34287786
    [Abstract] [Full Text] [Related]

  • 6. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct 03; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.
    J Headache Pain; 2021 Jul 23; 22(1):81. PubMed ID: 34301173
    [Abstract] [Full Text] [Related]

  • 12. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
    Storch P, Burow P, Möller B, Kraya T, Heintz S, Politz N, Naegel S.
    Acta Neurol Belg; 2022 Aug 23; 122(4):931-937. PubMed ID: 34406609
    [Abstract] [Full Text] [Related]

  • 13. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
    Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, Cevoli S, Pani L.
    Neurol Sci; 2022 Jun 23; 43(6):3823-3830. PubMed ID: 35015202
    [Abstract] [Full Text] [Related]

  • 14. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
    Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G.
    J Headache Pain; 2020 Jun 09; 21(1):69. PubMed ID: 32517693
    [Abstract] [Full Text] [Related]

  • 15. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, Cainazzo MM, Cortelli P, Pierangeli G, Guerzoni S, Cevoli S.
    Cephalalgia; 2022 Jun 09; 42(7):645-653. PubMed ID: 35135357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation.
    Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K, NHS Greater Glasgow and Clyde Headache Service.
    J Headache Pain; 2022 Jul 22; 23(1):86. PubMed ID: 35869443
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.